Simmerafil
 | |
| Clinical data | |
|---|---|
| Other names | TPN171 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C24H35N5O3 |
| Molar mass | 441.576 g·mol−1 |
Simmerafil[1] (TPN171H) is a selective PDE5 inhibitor[2] in development for the treatment of erectile dysfunction[3] and pulmonary hypertension.[4]
References
[edit]- ^ Odilov, Abdullajon; Liu, Yin; Hu, Tianwen; Jiang, Xiangrui; Suo, Jin; Tian, Guanghui; Yang, Feipu; Shen, Jingshan (19 November 2021). "Facile and Cost-Effective Route for the Synthesis of Simmerafil". Organic Process Research & Development. 25 (11): 2432–2437. doi:10.1021/acs.oprd.1c00184. ISSN 1083-6160. S2CID 244619662.
- ^ Qian, Hongjie; Chen, Qian; Liang, Liyu; Zou, Yang; Pu, Huahua; Xin, Liang; Song, Rong; Li, Tingting; Zhu, Huijuan; Wang, Yu; Tian, Guanghui; Shen, Jingshan; Jiang, Hualiang; Yu, Chen; Wang, Zhen; Jia, Jingying (2021). "A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects". Drug Design, Development and Therapy. 15: 2947–2959. doi:10.2147/DDDT.S308610. ISSN 1177-8881. PMC 8273902. PMID 34262260.
- ^ "Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction". www.clinicaltrials.gov. CTG Labs. Retrieved 9 November 2023.
- ^ Zhao, Congke; Hu, Liqing; He, Xiangrong; Li, Lijun; Yin, Minghui; Tettey, Abraham Terkpertey; Wang, Yu; Shen, Jingshan; Tang, Siyuan; Wu, Chunhui; Li, Qianbin; Wang, Zhen; Li, Xiaohui (1 August 2022). "TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats". Vascular Pharmacology. 145: 107017. doi:10.1016/j.vph.2022.107017. ISSN 1537-1891. PMID 35680060. S2CID 249490064.